ArticleInternational journal of environmental research and public health2019
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.Scientific reports · 2021Trial
- Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.Pediatric obesity · 2021Trial
- Trial
- Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.Endocrinology, diabetes & metabolism · 2026Review
- Costs of Comorbidities and Complications Associated with Type 2 Diabetes: A Retrospective, Cohort Study.Advances in therapy · 2026Article
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025.Obesity pillars · 2025Review
- Review
- Review
- GLP-1 and Its Analogs: Does Sex Matter?Endocrinology · 2025Review
- Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia.Journal of pharmacy & bioallied sciences · 2024Article
- Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.Journal of clinical medicine · 2024Article
- The alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 reduces food intake in male rats.Pharmacology, biochemistry, and behavior · 2024Article
- Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform.Journal of general internal medicine · 2024Article
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.Journal of diabetes research · 2024Observational
- Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.RSC medicinal chemistry · 2023Review
- A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.